US20020164357A1 - Methods for the production of non-covalently complexed and multivalent proteosome sub-unit vaccines - Google Patents

Methods for the production of non-covalently complexed and multivalent proteosome sub-unit vaccines Download PDF

Info

Publication number
US20020164357A1
US20020164357A1 US09/043,529 US4352998A US2002164357A1 US 20020164357 A1 US20020164357 A1 US 20020164357A1 US 4352998 A US4352998 A US 4352998A US 2002164357 A1 US2002164357 A1 US 2002164357A1
Authority
US
United States
Prior art keywords
proteosome
preparation
vaccine according
vaccine
amphiphilic determinant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
US09/043,529
Other versions
US6476201B1 (en
Inventor
George H. Lowell
Wendell D. Zollinger
James F. Wood
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ID Biomedical Corp of Washington
US Department of Army
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21707938&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20020164357(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Priority to US09/043,529 priority Critical patent/US6476201B1/en
Assigned to ID BIOMEDICAL CORPORATION OF QUEBEC reassignment ID BIOMEDICAL CORPORATION OF QUEBEC ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: LOWELL, GEORGE H.
Application granted granted Critical
Publication of US6476201B1 publication Critical patent/US6476201B1/en
Publication of US20020164357A1 publication Critical patent/US20020164357A1/en
Assigned to ID BIOMEDICAL CORPORATION OF MARYLAND reassignment ID BIOMEDICAL CORPORATION OF MARYLAND ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ID BIOMEDICAL CORPORATION OF QUEBEC
Assigned to UNITED STATES ARMY reassignment UNITED STATES ARMY ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ZOLLINGER, WENDELL D.
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
    • A23J1/00—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites
    • A23J1/008—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites from microorganisms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1275—Lipoproteins; Chylomicrons; Artificial HDL, LDL, VLDL, protein-free species thereof; Precursors thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/25—Shigella (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • This invention concerns methods of production and compositions for non-covalently complexed multivalent proteosome vaccines for mucosal and parenteral administration.
  • non-covalently complexed vaccines include proteosome vaccines which can consist of neisserial outer membrane protein proteosomes non-covalently complexed to a wide variety of antigens including peptides, lipopeptides, transmembrane or toxoided proteins, polysaccharides or lipopolysaccharides (LPS) (patent application Ser. Nos.
  • Dialysis tubing is not scalable since large amounts of product is problematic and 5) Inability to readily measure completeness of removal of the detergent so as to maximize vaccine effectiveness. Since the dialysis bag is placed in a container with 200 volumes of buffer, the ongoing measurement of detergent removal is neither practical nor feasible and 6) In addition, no method has been described for the measurement of the presence of the detergent used in the preferred embodiment, Empigen BB.
  • the second problem solved in this invention is the demonstration of the method of producing and delivering multivalent vaccines.
  • Components can either be made together or produced separately and mixed together prior to administration.
  • the instant invention demonstrates the optimal way of preparing such multivalent vaccines.
  • the subject of the instant invention broadly relates to the production and manufacture of proteosome-amphiphilic determinant vaccines designed for either parenteral or especially for mucosal administration including, but not limited to, respiratory (e.g. including intranasal, intrapharyngeaeal and intrapulmonary), gastro-intestinal (e.g. including oral or rectal) or topical (e.g. conjunctival or otic) administration to induce both systemic (serum) and mucosal (including respiratory and intestinal) antibody responses.
  • respiratory e.g. including intranasal, intrapharyngeaeal and intrapulmonary
  • gastro-intestinal e.g. including oral or rectal
  • topical e.g. conjunctival or otic
  • amphiphilic determinant is a molecule having hydrophobic and hydrophilic regions which, when appropriately formulated with proteosomes, align with the proteosomes to for a complex which elicits an immunologic response in a subject.
  • Typical amphiphilic determinants include glycolipids, liposaccharides (including detoxified lipopolysaccharides), lipopeptides, transmembrane, envelope or toxoided proteins, or proteins or peptides with intrinsic hydrophobic amino acid anchors. These determinant materials can be obtained from gram negative bacteria including escherichia, klebsiella, pseudomonas, hemophilus brucella, shigella and neisseria.
  • the invention relates to proteosome vaccines in which meningococcal outer membrane protein proteosome preparations (prepared from any strain of N. meningiditis or N. gonorrhea or other neisserial species) are non-covalently complexed to native or detoxified shigella or neisserial lipopolysaccharides or lipooligosaccharides to form vaccines designed to protect against diseases caused by gram negative organisms that contain any of the component parts of the complex including meningococci or shigellae.
  • meningococcal outer membrane protein proteosome preparations prepared from any strain of N. meningiditis or N. gonorrhea or other neisserial species
  • native or detoxified shigella or neisserial lipopolysaccharides or lipooligosaccharides to form vaccines designed to protect against diseases caused by gram negative organisms that contain any of the component parts of the complex including meningococci or shigella
  • the invention relates to proteosome vaccines that contain LPS that induce antibody responses that recognize type-specific somatic polysaccharide O-antigens of shigella lipopolysaccharides and thereby confer homologous protection against shigellosis.
  • the lipopolysaccharides that, when complexed to proteosomes induce such anti-shigella protective immune responses are prepared and purified from either Shigella sonnei or Plesiomonas shigelloides for immunity against Shigella sonnei disease, from Shigella flexneri 2a for immunity to Shigella flexneri 2a disease, and so forth, using LPS derived from homologous or antigenically cross-reacting organisms to confer homologous immunity against shigellosis caused by S. flexneri 2a (or 3a etc.), S. boydii, S. sonnei etc.
  • the instant invention describes the successful administration of proteosome-shigella vaccines that are multivalent in that two independently made proteosome vaccines using shigella LPSs derived from S. flexneri 2a (for S. flexneri 2a disease) and from P. shigelloides or S. sonnei (for S. sonnei disease) are administered together thereby inducing antibodies that recognize the two organisms and thereby conferring protection against the two types of diseases.
  • the instant invention relates to a proteosome-shigella LPS vaccine in which proteosomes from group B type 2b meningococci are complexed to P.
  • shigelloides LPS using hollow fiber diafiltration technology to produce a vaccine administered by mucosal respiratory and/or gastro-intestinal routes to induce antibodies that recognize the somatic O-antigen LPS of S. sonnei and thereby protect against shigellosis caused by this organism.
  • Other conventional ultrafiltration/diafiltration are envisioned, e.g. platform membrane and membrane cartridge.
  • the present invention provides methodology to produce non-covalently complexed vaccines in a manner that 1) Decreases the time required, 2) Decreases the opportunity for contamination, 3) Increases the temperature to ambient temperature that such vaccines can be produced, 4) Allows for efficient scale-up of the production process so as to require minimum use of reagents, 5) Allows for reliable and efficient sampling of dialysate so as to be able to repeatedly measure rate of removal of the detergent so as to optimize efficiency of the operation. This leads directly to an increase in the complexing efficiency of vaccine so as to produce vaccine with measurably greater immunogenicity at lower doses. In this manner, the overall quality of the product is significantly enhanced.
  • the method of the instant invention entails the use of a hollow fiber ultrafiltration/diafiltration cartridge to effect complexing by removal of the detergent.
  • the time of dialysis for production of a lot of vaccine can be reduced from >7-10 days to less than 72 hours and usually less than 48 or 24 hours. Since this short time is used, the reaction temperature can be increased from 4° to normal room temperature without compromising the process or the integrity of the products. While the process was performed at about 20° C., temperatures between 0° and 40° C. are contemplated. Since the system is closed, there is a highly reduced potential for contamination.
  • the permeate can be repeatedly sampled to measure the removal of the detergent as can be accomplished using the test of the instant invention to measure the presence of the detergent empigen BB, the detergent used in the preferred embodiment.
  • the uniqueness of this methodology needed experimental verification since it was not obvious that the complexing and the structure of the vaccine into immunogenic materials that was accomplished by slowly dialyzing over 7-10 days using a stationary dialysis bag could be equalled or improved upon using the hollow fiber technology in which the moieties to be complexed are moving through tubes at exceedingly high flow rates compared to that of the stationary dialysis tube.
  • the nominal molecular weight cutoff of the membrane used can be selected to be from 1,000, 3,000, 5,000, 10,000, 30,000, 50,000 or greater, depending on the size of the components to be non-covalently complexed, this system is readily adaptable to the complexing of native or detoxified lipopolysaccharides, lipids, peptides, lipopeptides, liposaccharides, polysaccharides, gangliosides or transmembrane, envelope or native or toxoided proteins to each other or to meningococcal outer membrane protein preparations of proteosomes.
  • the resultant product can be used as a vaccine administered either parenterally or mucosally i.e. via the respiratory or gastro-intestinal tract e.g. intranasally, orally, by oropharyngeal inhalant, topically or rectally.
  • proteosomes are non-covalently complexed to P. shigelloides LPS to form a vaccine that induces the anti- S. sonnei LPS responses necessary for protection against S. sonnei shigellosis.
  • the methodology has three stages: a preliminary operation; complexing the proteosome with an amphiphilic determinant e.g. P. Shigelloides LPS; followed by a sterile filtration.
  • an amphiphilic determinant e.g. P. Shigelloides LPS
  • the present invention shows that the best method is to make the specific vaccines individually and then immunize with the two individually made vaccines, each at the optimal concentration, on the same day.
  • Other possibilities such as making hybrid vaccines during the formation of the non-covalent complexes have also been accomplished or are envisioned.
  • FIG. 1 Intranasal immunization with proteosome- P. shigelloides LPS Vaccine: serum IgG responses elicited by several preparations at decreased doses.
  • FIG. 2 Intranasal immunization with Proteosome- P. shigelloides LPS vaccine: serum IgA responses elicited by several preparations at decreased doses.
  • FIG. 3 Administration of the proteosome- P. shigelloides LPS (for S. sonnei shigellosis) and the proteosome- S. flexneri 2a vaccines together on the same day or weeks apart results in good immunogenicity to both the S. sonnei and S. flexneri 2a LPS components.
  • FIG. 4 Immunogold labelled electron micrograph of proteosome-shigella LPS vaccine showing association of shigella LPS with proteosome vesicles.
  • FIG. 5 Proteosome- P. Shigelloides LPS vaccine protects against lethal Shigella sonnei pneumonia in an animal model of Shigellosis.
  • FIG. 6 Intranasal or oral immunization with proteosome-shigella flexneri 2a LPS vaccines induce anti-shigella LPS IgG and IgA in serum and IgA in intestinal and lung lavage fluids that can last 30-60 days post-immunization.
  • FIG. 7 Intranasal or oral immunization of humans with one or two doses proteosome-p.
  • shigelloides LPS vaccines for Shigella sonnei using different vaccine amounts Induction of anti-shigella LPS IgA, IgG and IgM peripheral blood ASC responses, and serum, salivary and urinary antibody responses.
  • FIG. 8 LPS in HPLC fractions after applying uncomplexed P. shigelloides LPS and Demonstration of non-covalent complexing of LPS and proteosome proteins by co-elution of LPS and proteins in HPLC fractions after applying proteosome- P. shigelloides LPS vaccine.
  • FIG. 9 Bactericidal antibody response of mice to meningococcal outer membrane protein-detoxified lipooligosaccharide vaccine, geometric mean reciprocal titers against meningococcal strain 9162
  • proteosome- P. shigelloides vaccine containing approximately 2-3 grams of protein.
  • the procedure is equally applicable for scale-up using 10-1000 fold more material with appropriate scale-up of housing size of the membrane cartridge and appropriate increases in the volumes.
  • this procedure is equally applicable for complexing of proteosomes to other native or detoxified lipopolysaccharides, lipids, peptides, lipopeptides, liposaccharides, polysaccharides, gangliosides or transmembrane, envelope or native or toxoided proteins to each other or to meningococcal outer membrane protein preparations of proteosomes.
  • Empigen BB is the detergent used as an example in this procedure; the procedure applies equally to any dialyzable detergent that solubilizes the components. This procedure uses A/G technology cartridges but is equally applicable to any brand cartridge type ultrafiltration/diafiltration system.
  • the ultrafiltration system is cleaned and sanitized with WFI and 0.5N NaOH at a temperature of 50° C. for a time greater than 60 minutes. This system is flushed with WFI and equilibrated with TNS buffer prior to use.
  • a sterile reservoir vessel is placed in line so that the inlet liquid is pulled from the vessel and the return retentate returned to the same reservoir.
  • TNS buffer either by direct addition or by a continuous feed system.
  • the complexes may, if desired, be sterile filtered. Proteosome concentration can be adjusted before or after 0.221 ⁇ filtering. Sterile filtration is normally performed with filter units from Millipore Corp. These units are called Millipaks and they come in various sizes. The filtered bulk is stored at 4° C. until the fill operation and is tested for sterility.
  • This GMP procedure results in the production of a bulk preparation formation of non-covalent complexes of proteosomes with S. flexneri 2a lipopolysaccharide for use as a vaccine against S. flexneri 2a infection.
  • the assay for protein was by absorbance at 280 nm, and the assay for LOS was by inhibition of an ELISA (enzyme linked immunosorbant assay) in which an L8 monoclonal antibody binding to purified L8 LOS adsorbed to the plastic plate was inhibited by serial dilutions of the fractions off the Sephacryl column.
  • ELISA enzyme linked immunosorbant assay
  • the LOS came off the column in a broad peak centered at fraction 39 .
  • the LOS co-eluted with the proteosomes in a peak approximately centered at fraction 33 .
  • This GMP procedure results in the production of a bulk preparation formation of non-covalent complexes of proteosomes with detoxified meningococcal lipopolysaccharide for use as a vaccine against N. meningitides (meningococcal) infection.
  • This example is also directed to the production of proteosome- P. shigelloides vaccine.
  • the procedure is equally applicable for scale-up using 10-1000 fold more material with appropriate scale-up of housing size of the membrane cartridge and appropriate increases in the volumes.
  • TNS consists of 0.15 M sodium chloride, 0.05 M Tris Buffer pH 8.0 ⁇ 0.2
  • LPS lipopolysaccharide
  • step 5.9.2.3 From the cylinder in step 5.9.2.2, transfer to another clean, sterile, 1 L graduated cylinder, a volume of proteosomes containing the amount in mg equal to the mg amount of LPS used in step 5.9.1.2.
  • the complexes may, if desired, be sterile filtered. Obtain the bulk complexed proteosomes and LPS and inspect for the presence of any precipitate or cloudiness. If the bulk complexed product is clear, aseptically filter it using a Millipak 40, 0.22 ⁇ filtration unit into a sterile, depyrogenated vessel. This step is to be done in a Sterile Cabinet.
  • This GMP procedure results in the production of a bulk preparation formation of non-covalent complexes of proteosomes with P. shigelloides 2a lipopolysaccharide for use as a vaccine against Shigella sonnei infection.
  • FIGS. 1 and 2 demonstrate that three different proteosome-shigella LPS vaccine preparations made using the hollow fiber (HF) diafiltration technique (HF-1, HF-2 and GMP/HF-3) to remove detergent and facilitate complexing are more effective at the lowest, most stringent dose tested, than preparations made using simple dialysis tubing (DT).
  • HF hollow fiber
  • HF-2 hollow fiber diafiltration technique
  • GMP/HF-3 hollow fiber diafiltration technique
  • the stronger responses are elicited by the vaccine when administered at the lowest dose (0.1 ug per dose) thereby indicating that less vaccine would be needed using the instant invention than would be required using the older technology. Since in the formulation of multivalent vaccines requires many different antigens, in order to minimize the total amount of vaccine administered, it is highly advantageous to be able to use vaccine components that are effective at lower doses. Thus, the technology of the instant invention to produce vaccines using the hollow fiber technology directly impacts and facilitates the ability to formulate multivalent vaccines having a wide range of specificities.
  • the proteosome- P. shigelloides LPS vaccine consistently confers highly significant protection against lethal infection with P. shigelloides as measured in an animal model of shigellosis in which the animals are challenged with live organisms to induce lethal pneumonia.
  • proteosome vaccines can stimulate the common mucosal immune system to secrete specific antibodies even at locations far away from the immunizing site.
  • intranasal immunization can induce antibodies in intestinal secretions and vice versa. This ability expands the potential utility of proteosome vaccines to protect against pathogens that invade the host through the mucosal portals of entry throughout the body.
  • FIG. 7 shows the induction of anti-shigella LPS IgA, IgG and IgM peripheral blood ASC responses, and serum, salivary and urinary IgA and IgG antibody responses after intranasal or oral immunization of human volunteers with one or two doses proteosome- P. shigelloides LPS vaccines for Shigella sonnei using different vaccine amounts. As shown, intranasal immunization elicited responses in a dose dependant fashion with the highest dose inducing responses in all six volunteers.
  • IgA, IgG and IgM serum responses were elicited in each of the intranasal groups.
  • strong antibody secreting cell ASC responses were induced indicating that mucosal immunization stimulated trafficking of antibody secreting cells—most notably, IgA-secreting cells.
  • IgA responses were also found in salivary and, especially, urinary samples indicating that secretory IgA was produced at mucosal surfaces (since IgA does not pass through the kidney, the urinary IgA reflects local secretion of antibody and suggests that such intranasal vaccines also produce local intestinal IgA and that intranasal vaccines could be used to protect against urinary tract infections caused by gram negative organisms.) It is noteworthy that the majority of these ASC and antibody responses were found after only one immunization suggesting that booster immunization may not be necessary. IgA and IgG ASCs and urinary IgA were also found after oral immunization. The most effective use of oral administration may be as a booster immunization after nasal priming, if necessary.
  • FIG. 8 Demonstration of non-covalent complexing of the multimolecular proteosome proteins and LPS is shown in FIG. 8.
  • the graph shows LPS in HPLC fractions after applying uncomplexed P. shigelloides LPS which occurs at a different part of the column elution profile than when applying the proteosome-LPS vaccine.
  • the co-elution of LPS and proteins in HPLC fractions after applying proteosome- P. shigelloides LPS vaccine is shown with peaks that correspond to the largest protein aggregates of proteosomes.
  • the data were measured using an inhibition ELISA to quantitate the LPS and using the OD at A280 to quantitate the proteosome proteins.
  • the HPLC column was a Tosohaas G50000Pwx1 and the molecular weight standards are indicated by the arrows.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Dispersion Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

A method for preparing multivalent proteosomeamphiphilic determinant vaccines suitable for parenteral or mucosal administration using diafiltration or ultrafiltration technology. The amphiplilic determinants include lipopolysaccharides from gram negative bacteria, e.g. S. flexneri, P. shigelloides and S. sonnei. Proteosomes are obtained from group B type 2b meningococci. The active proteosomeamphiphilic determinant complexes (noncovalently complexes) of the vaccine are formed using defiltration or ultrafiltration to remove the detergent. The use of diafiltration or ultrafiltration decreases processing time and the opportunity for contamination and further permits the use of ambient temperature and efficient scaleup. In addition, the process permits the reliable and continuous monitoring of the dialysate which enhances the efficiency of the entire process. The time of dialysis for production of a lot of vaccine is reduced from 710 days to less than 72 hours and usually less than 48 or 4 hours. The use of the process optimizes the presence of each antigenic component in the preparation of multivalent vaccines.

Description

    1. FIELD OF THE INVENTION
  • This invention concerns methods of production and compositions for non-covalently complexed multivalent proteosome vaccines for mucosal and parenteral administration. [0001]
    • 2. BACKGROUND OF THE INVENTION
  • In order for multivalent sub-unit vaccines to stimulate optimal immune responses to each of the components, the proper components should be appropriately associated and each be available to the immune system so that they may be efficiently recognized and processed by cells of the immune system. Prime examples of such non-covalently complexed vaccines include proteosome vaccines which can consist of neisserial outer membrane protein proteosomes non-covalently complexed to a wide variety of antigens including peptides, lipopeptides, transmembrane or toxoided proteins, polysaccharides or lipopolysaccharides (LPS) (patent application Ser. Nos. 07/065,440 filed Jun, 23, 1987 “Immunogenic peptide vaccines and methods of preparation”; 07/336,952 filed Apr. 12, 1989 Immunopotentiaing system for large proteins and polypeptides”; 07-958,426 filed Oct. 8, 1992 “Oral or Intranasal Vaccines Using Hydrophobic Complexes Having Proteosomes and Lipopolysaccharides”; 08/029,666 filed Mar. 11, 1993 “Immunopotentiating Systems for Preparation of Immunogenic Materials”; 08/143,365 filed Oct. 29, 1993 “Immunopotentiating Systems for Preparation of Immunogenic Materials”; 93/10,402 filed Oct. 29, 1993 “Submicron Emulsions as Vaccine Adjuvants”; 08/063,613 filed May 18, 1994 Solid Fat Nanoemulsions as Vehicles for Vaccine Delivery” and publications Orr, N., Robin, G., Cohen, D., Arnon, R. and Lowell, G. H. (1993). Immunogenicity and Efficacy of Oral or Intranasal [0002] Shigella flexneri 2a and Shigella sonnei Proteosome-Lipopolysaccharide Vaccines in Animal Models. Infect. Immun. 61:2390; Mallett, C. P., T. L. Hale, R. Kaminski, T. Larsen, N. Orr, D. Cohen, and G. H. Lowell. 1995. Intranasal or intragastric immunization with proteosome-Shigella lipopolysaccharide vaccines protect against lethal pneumonia in a murine model of shigellosis. Infect. Immun. 63:2382-2386.; Lowell G H, Kaminski R W, Grate S et al. (1996) Intranasal and intramuscular proteosome-staphylococcal enterotoxin B (SEB) toxoid vaccines: immunogenicity and efficacy against lethal SEB intoxication in mice. Infec. Immun. 64:1706-1713.; Lowell, G. H. (1990) Proteosomes, Hydrophobic Anchors, Iscoms and Liposomes for Improved Presentation of Peptide and Protein Vaccines. in New Generation Vaccines: G. C. Woodrow and M. M. Levine, eds. (Marcel Dekker, NY). Chapter 12 (pp. 141-160) and Lowell, G. H., W. R. Ballou, L. F. Smith, R. A. Wirtz, W. D. Zollinger and W. T. Hockmeyer. 1988. Proteosome-lipopeptide vaccines: enhancement of immunogenicity for malaria CS peptides. Science 240:800.)
  • The contents of all the documents cited herein are expressly incorporated by reference. [0003]
  • For practical application in administering vaccines to protect against disease, it is frequently necessary to deliver several such antigens at the same time usually due to the fact that individuals are susceptible to the contraction of diseases caused by a variety of organisms. Moreover, several organisms, whether or not they are related to one another, often are endemic in the same location and therefore individuals requiring protection may need vaccination with several types of vaccines. [0004]
  • In the past, the production of vaccines that require non-covalent complexing of components has been accomplished using simple dialysis in which components are placed in dialysis tubing in the presence of dialyzable detergent and the mixture is dialyzed for 7-10 days to attempt to remove the detergent. The practical disadvantages of this system tend to severely preclude the advanced development and commercialization of this technology for several reasons including 1) Time: Length of time of the procedure: The need to use GMP resources for weeks while the vaccine is dialyzing is impractical both due to the excess costs involved and the increased opportunity for breakdown or contamination of mechanical or biological components during this extended period of time; 2) Contamination: Increased opportunity for contamination: dialysis tubing is difficult to sterilize, dialysis tubing requires manually opening and closing the system thereby exposing the components to contamination during both the loading and unloading process. Since many days transpire between loading and unloading the tubing, the risk of a small contamination in the initial days of the process may readily be magnified during the many days of dialysis to render this method useless for practical vaccine manufacture. The risk of puncturing the bag can result in loss of product. 3) Temperature: Necessity to perform the dialysis at 4° C. due to the extensive time involved; 4) Volume of dialyzing fluids: In order to manufacture vaccine for scale-up of the process, the use of massive amounts of dialysis fluid would be necessary since a 200:1 ratio of liquid outside to the dialysis tubing to inside the tubing is typically required. Therefore, for example, the production of a pilot lot of two liters of vaccine would require 400 liters of fluid outside the tubing per day—4,000 liters per 10 days—and the production of a production lot of 20-200 liters would require 40,000-4,000,000 liters. These amounts are wasteful and impractical compared to the method used in the instant invention; Dialysis tubing is not scalable since large amounts of product is problematic and 5) Inability to readily measure completeness of removal of the detergent so as to maximize vaccine effectiveness. Since the dialysis bag is placed in a container with 200 volumes of buffer, the ongoing measurement of detergent removal is neither practical nor feasible and 6) In addition, no method has been described for the measurement of the presence of the detergent used in the preferred embodiment, Empigen BB. [0005]
  • The second problem solved in this invention is the demonstration of the method of producing and delivering multivalent vaccines. Components can either be made together or produced separately and mixed together prior to administration. The instant invention demonstrates the optimal way of preparing such multivalent vaccines. [0006]
    • 3. SUMMARY OF THE INVENTION
  • The subject of the instant invention broadly relates to the production and manufacture of proteosome-amphiphilic determinant vaccines designed for either parenteral or especially for mucosal administration including, but not limited to, respiratory (e.g. including intranasal, intrapharyngeaeal and intrapulmonary), gastro-intestinal (e.g. including oral or rectal) or topical (e.g. conjunctival or otic) administration to induce both systemic (serum) and mucosal (including respiratory and intestinal) antibody responses. An amphiphilic determinant is a molecule having hydrophobic and hydrophilic regions which, when appropriately formulated with proteosomes, align with the proteosomes to for a complex which elicits an immunologic response in a subject. Typical amphiphilic determinants include glycolipids, liposaccharides (including detoxified lipopolysaccharides), lipopeptides, transmembrane, envelope or toxoided proteins, or proteins or peptides with intrinsic hydrophobic amino acid anchors. These determinant materials can be obtained from gram negative bacteria including escherichia, klebsiella, pseudomonas, hemophilus brucella, shigella and neisseria. More specifically, the invention relates to proteosome vaccines in which meningococcal outer membrane protein proteosome preparations (prepared from any strain of [0007] N. meningiditis or N. gonorrhea or other neisserial species) are non-covalently complexed to native or detoxified shigella or neisserial lipopolysaccharides or lipooligosaccharides to form vaccines designed to protect against diseases caused by gram negative organisms that contain any of the component parts of the complex including meningococci or shigellae. More specifically, the invention relates to proteosome vaccines that contain LPS that induce antibody responses that recognize type-specific somatic polysaccharide O-antigens of shigella lipopolysaccharides and thereby confer homologous protection against shigellosis. Still more specifically, the lipopolysaccharides that, when complexed to proteosomes induce such anti-shigella protective immune responses are prepared and purified from either Shigella sonnei or Plesiomonas shigelloides for immunity against Shigella sonnei disease, from Shigella flexneri 2a for immunity to Shigella flexneri 2a disease, and so forth, using LPS derived from homologous or antigenically cross-reacting organisms to confer homologous immunity against shigellosis caused by S. flexneri 2a (or 3a etc.), S. boydii, S. sonnei etc. Still more specifically, the instant invention describes the successful administration of proteosome-shigella vaccines that are multivalent in that two independently made proteosome vaccines using shigella LPSs derived from S. flexneri 2a (for S. flexneri 2a disease) and from P. shigelloides or S. sonnei (for S. sonnei disease) are administered together thereby inducing antibodies that recognize the two organisms and thereby conferring protection against the two types of diseases. Most specifically, the instant invention relates to a proteosome-shigella LPS vaccine in which proteosomes from group B type 2b meningococci are complexed to P. shigelloides LPS using hollow fiber diafiltration technology to produce a vaccine administered by mucosal respiratory and/or gastro-intestinal routes to induce antibodies that recognize the somatic O-antigen LPS of S. sonnei and thereby protect against shigellosis caused by this organism. Other conventional ultrafiltration/diafiltration are envisioned, e.g. platform membrane and membrane cartridge.
  • The present invention provides methodology to produce non-covalently complexed vaccines in a manner that 1) Decreases the time required, 2) Decreases the opportunity for contamination, 3) Increases the temperature to ambient temperature that such vaccines can be produced, 4) Allows for efficient scale-up of the production process so as to require minimum use of reagents, 5) Allows for reliable and efficient sampling of dialysate so as to be able to repeatedly measure rate of removal of the detergent so as to optimize efficiency of the operation. This leads directly to an increase in the complexing efficiency of vaccine so as to produce vaccine with measurably greater immunogenicity at lower doses. In this manner, the overall quality of the product is significantly enhanced. 6) In addition, a method is described to measure the presence of the detergent used in the preferred embodiment, Empigen BB. Other dialyzable detergents can be used in place of Empigen BB. Furthermore, using the method of the instant invention, it has been demonstrated that the vaccine can be lyophilized and re-hydrated in such a manner as to retain optimal vaccine potency as measured by vaccine immunogenicity. [0008]
  • The method of the instant invention entails the use of a hollow fiber ultrafiltration/diafiltration cartridge to effect complexing by removal of the detergent. By varying the size of the housing of the cartridge, the time of dialysis for production of a lot of vaccine can be reduced from >7-10 days to less than 72 hours and usually less than 48 or 24 hours. Since this short time is used, the reaction temperature can be increased from 4° to normal room temperature without compromising the process or the integrity of the products. While the process was performed at about 20° C., temperatures between 0° and 40° C. are contemplated. Since the system is closed, there is a highly reduced potential for contamination. In addition, by increasing the size of the housing, an exceedingly large amount of material can be processed in a relatively short period of time thereby allowing for efficient and reproducible scale-up of the procedure for commercial development. Furthermore, the permeate can be repeatedly sampled to measure the removal of the detergent as can be accomplished using the test of the instant invention to measure the presence of the detergent empigen BB, the detergent used in the preferred embodiment. The uniqueness of this methodology needed experimental verification since it was not obvious that the complexing and the structure of the vaccine into immunogenic materials that was accomplished by slowly dialyzing over 7-10 days using a stationary dialysis bag could be equalled or improved upon using the hollow fiber technology in which the moieties to be complexed are moving through tubes at exceedingly high flow rates compared to that of the stationary dialysis tube. [0009]
  • Since the nominal molecular weight cutoff of the membrane used can be selected to be from 1,000, 3,000, 5,000, 10,000, 30,000, 50,000 or greater, depending on the size of the components to be non-covalently complexed, this system is readily adaptable to the complexing of native or detoxified lipopolysaccharides, lipids, peptides, lipopeptides, liposaccharides, polysaccharides, gangliosides or transmembrane, envelope or native or toxoided proteins to each other or to meningococcal outer membrane protein preparations of proteosomes. [0010]
  • The resultant product can be used as a vaccine administered either parenterally or mucosally i.e. via the respiratory or gastro-intestinal tract e.g. intranasally, orally, by oropharyngeal inhalant, topically or rectally. In the example given, it is shown that proteosomes are non-covalently complexed to [0011] P. shigelloides LPS to form a vaccine that induces the anti-S. sonnei LPS responses necessary for protection against S. sonnei shigellosis.
  • The methodology has three stages: a preliminary operation; complexing the proteosome with an amphiphilic determinant e.g. [0012] P. Shigelloides LPS; followed by a sterile filtration.
  • To optimally deliver multivalent vaccines, the present invention shows that the best method is to make the specific vaccines individually and then immunize with the two individually made vaccines, each at the optimal concentration, on the same day. Other possibilities such as making hybrid vaccines during the formation of the non-covalent complexes have also been accomplished or are envisioned.[0013]
    • 4. BRIEF DESCRIPTION OF THE FIGURES
  • FIG. 1: Intranasal immunization with proteosome-[0014] P. shigelloides LPS Vaccine: serum IgG responses elicited by several preparations at decreased doses.
  • FIG. 2: Intranasal immunization with Proteosome-[0015] P. shigelloides LPS vaccine: serum IgA responses elicited by several preparations at decreased doses.
  • FIG. 3: Administration of the proteosome-[0016] P. shigelloides LPS (for S. sonnei shigellosis) and the proteosome- S. flexneri 2a vaccines together on the same day or weeks apart results in good immunogenicity to both the S. sonnei and S. flexneri 2a LPS components.
  • FIG. 4: Immunogold labelled electron micrograph of proteosome-shigella LPS vaccine showing association of shigella LPS with proteosome vesicles. [0017]
  • FIG. 5: Proteosome-[0018] P. Shigelloides LPS vaccine protects against lethal Shigella sonnei pneumonia in an animal model of Shigellosis.
  • FIG. 6: Intranasal or oral immunization with proteosome-[0019] shigella flexneri 2a LPS vaccines induce anti-shigella LPS IgG and IgA in serum and IgA in intestinal and lung lavage fluids that can last 30-60 days post-immunization.
  • FIG. 7: Intranasal or oral immunization of humans with one or two doses proteosome-p. shigelloides LPS vaccines for [0020] Shigella sonnei using different vaccine amounts: Induction of anti-shigella LPS IgA, IgG and IgM peripheral blood ASC responses, and serum, salivary and urinary antibody responses.
  • FIG. 8: LPS in HPLC fractions after applying uncomplexed [0021] P. shigelloides LPS and Demonstration of non-covalent complexing of LPS and proteosome proteins by co-elution of LPS and proteins in HPLC fractions after applying proteosome-P. shigelloides LPS vaccine.
  • FIG. 9: Bactericidal antibody response of mice to meningococcal outer membrane protein-detoxified lipooligosaccharide vaccine, geometric mean reciprocal titers against meningococcal strain 9162[0022]
    • 5. DETAILED DESCRIPTION OF THE INVENTION EXAMPLE 1
  • This example is detailed for production of proteosome-[0023] P. shigelloides vaccine containing approximately 2-3 grams of protein. The procedure is equally applicable for scale-up using 10-1000 fold more material with appropriate scale-up of housing size of the membrane cartridge and appropriate increases in the volumes. Using the appropriate size membranes with appropriate size molecular weight cutoffs to retain the antigens to be complexed, this procedure is equally applicable for complexing of proteosomes to other native or detoxified lipopolysaccharides, lipids, peptides, lipopeptides, liposaccharides, polysaccharides, gangliosides or transmembrane, envelope or native or toxoided proteins to each other or to meningococcal outer membrane protein preparations of proteosomes. Empigen BB is the detergent used as an example in this procedure; the procedure applies equally to any dialyzable detergent that solubilizes the components. This procedure uses A/G technology cartridges but is equally applicable to any brand cartridge type ultrafiltration/diafiltration system.
    • 5.0.0.1 Preliminary Operation
  • 5.0.0.1. Sterile filter a stock solution of 30% Empigen BB, which is the detergent used in this process. [0024]
  • 5.0.0.2. Prepare 2×TEEN/2% Empigen (0.1M Tris, 0.02 M disodium EDTA, 0.3 M sodium chloride, WFI and 2% Empigen, pH 8.0) [0025]
  • 5.0.0.3. Prepare 150 L of a TNS (Tris Normal Saline) solution containing 0.05M Tris, 0.15M sodium chloride pH 8.0 for the purpose of dialyzing out the detergent. [0026]
  • 5.0.0.4. Prepare 10 liters of Sodium Hydroxide for UF cartridge cleaning. [0027]
  • 5.0.0.5. Thaw the required amount of [0028] Shigella flexneri 2a Lipopolysaccharide (LPS).
    • 5.0.1. Complexing Proteosomes with S. flexneri 2a LPS
  • 5.0.1.6. Add an equal volume of 2×TEEN buffer to the volume of LPS and mix well. [0029]
  • 5.0.1.7. Thaw and measure an amount of bulk proteosomes, in mg's, equal to the amount of LPS thawed in [0030] step 5.
  • 5.0.1.8. To the proteosomes, add 30 ml of sterile filtered empigen per liter. Mix well and combine with the LPS from [0031] step 5.
  • 5.0.1.9. Mix both components well. Usually 15 minutes on a stir plate and stir bar combination is adequate. [0032]
  • 5.0.1.10. To dialyze the detergent out so that proteosome complexes could form, set up an ultrafiltration system (based on tangential flow technology} using a hollow fiber cartridge with a nominal molecular weight cutoff (NMWC) pore size of 10,000 manufactured by A/G Technology, Inc. connected to sterilized silicone tubing and a peristaltic pump. Sanitary pressure gauges are placed on the inlet and outlet side of the cartridge to monitor pressure throughout the run. A back pressure valve is placed on the outlet side of the cartridge to as to adjust back pressure. [0033]
  • 5.0.1.11. The ultrafiltration system is cleaned and sanitized with WFI and 0.5N NaOH at a temperature of 50° C. for a time greater than 60 minutes. This system is flushed with WFI and equilibrated with TNS buffer prior to use. [0034]
  • 5.0.1.12. A sterile reservoir vessel is placed in line so that the inlet liquid is pulled from the vessel and the return retentate returned to the same reservoir. As liquid passes through the cartridge membrane (permeate or filtrate) it is replenished by TNS buffer either by direct addition or by a continuous feed system. Set up a continuous feed system by connecting silicone tubing to a vessel containing TNS buffer to the sample reservoir that is then air tight. As the liquid is removed by filtration from the sample reservoir a vacuum is created causing “TNS” buffer to be pulled from the its vessel into the sample reservoir. If the system remains air tight the sample level it the reservoir remains constant. [0035]
  • 5.0.1.13. Start the recirculation pump to begin diafiltration. Adjust the pump speed and the back pressure valve to obtain a back pressure of 15±4 psi. [0036]
  • 5.0.1.14. Verify progressive removal of Empigen BB by testing permeate samples taken every 10-15 liters using the Empigen Precipitin Test. This test consists of making serial dilutions of the permeate and of a standard solution containing a known quantity of empigen BB, adding HCl to acidify the solutions and then adding serial dilutions of SDS (sodium dodecyl sulfate) to form a checkerboard-type assay. Maximum precipitate will form when equivalent amounts of empigen and SDS are present. In this manner, the amount of empigen present can be quantitated by noting the dilution of the SDS, the permeates and of the standards at which the maximum precipitate is formed. As the diafiltration progresses, the amount of empigen becomes less and the tube containing less SDS will be the tube with the maximum precipitate. The presence of precipitate is quantitated by measuring the OD at 600 nm using a spectrophotometer. [0037]
  • 5.0.1.15. For the amount of components used in this example, continue diafiltration until at least 120 liters of permeate has been processed and there is a lack of significant precipitate in the Empigen Precipitin Test (Maximum OD 600 nm is less than 0.05). [0038]
  • 5.0.1.16. After dialysis is complete concentrate the product to a final volume to get an OD[0039] 280 value close to 6.0. Drain the system and wash with 300-400ml of “TNS” buffer. Drain the system again and combine both pools. Clean the cartridge by recirculating large amounts of WFI followed by 0.5N NaOH at 50° C. for >60 minutes. Rinse out the NaOH with WFI and store the system in 0.01N NaOH.
    • 5.0.2. Sterile Filtration
  • 5.0.2.17. The complexes may, if desired, be sterile filtered. Proteosome concentration can be adjusted before or after 0.221μ filtering. Sterile filtration is normally performed with filter units from Millipore Corp. These units are called Millipaks and they come in various sizes. The filtered bulk is stored at 4° C. until the fill operation and is tested for sterility. [0040]
    • 5.0.3.0 Specific Purpose
  • Combine bulk GMP preparations of meningococcal outer membrane protein proteosomes and [0041] S. flexneri 2a lipopolysaccharide into non-covalent complexes by removal of detergent.
    • 5.0.3.1 Applications
  • This GMP procedure results in the production of a bulk preparation formation of non-covalent complexes of proteosomes with [0042] S. flexneri 2a lipopolysaccharide for use as a vaccine against S. flexneri 2a infection.
    • EXAMPLE 2
  • Noncovalent complexing of bulk [0043] Neisselia meningitidis strain 9162 purified outer membrane proteins (proteosomes) and alkaline detoxified N. meningitidis L8 lipooligosaccharide purified from strain 8532.
  • 5.1.0 Bulk 9162 outer membrane protein (proteosomes), lot 0136 and bulk detoxified meningococcal L8 Lipooligosaccharide (LOS) lot 0203 were taken from storage and thawed at room temperature. A volume (182 ml) of the bulk LOS containing 500 mg LOS in sterile distilled water was combined with a volume (306 ml) of bulk proteosomes containing 400 mg of protein in buffer containing 0.05 M Tris-HCl, 0.15 M NaCl, 0.01 M EDTA, and 0.1% Empigen BB. [0044]
  • 5.1.2 Empigen BB (30% solution) was sterile filtered through a 0.22 μm pore size filter and {fraction (1/60)}[0045] th volume added to the combined proteosomes, LOS solution and stirred at room temperature for 1 hour.
  • 5.1.3 The detergent buffer solution was removed from the proteosomes, LOS solution and replaced with sterile distilled water by ultrafiltration using an A/G Technology ultrafiltration cartridge UFP-3-C-6 with a 3000 molecular weight cut off pore size. [0046]
  • 5.1.4 The procedure for set up, sanitization, washing, washing, and cleaning of the apparatus was the same as described in example 1. Inlet pressure was 15±4 PSI and the permeate flow rate was 175 ml per minute. [0047]
  • 5.1.5 The permeate was tested after each 3 to 4 liters for the presence of Empigen BB detergent by the precipitation method described in example 1. The ultrafiltration was continued until no precipitate was obtained in the test plus an additional 5 liters. A total of 37 liters of permeate was collected. [0048]
  • 5.1.6 The retentate was clear and was sterile filtered through a 0.22 μm pore size filter assayed for protein and LOS and stored as a bulk product at 4° C. [0049]
  • 5.1.7 The bulk product was diluted to a concentration of 0.2 mg of protein per ml and the concentration of NaCl adjusted to 0.15 M. Thimerasol at 0.01% was added as a preservative, and the resulting bulk was dispensed under sterile conditions into final container vials, labelled and stored at −70° C. [0050]
  • 5.1.8 This product was tested in mice for immunogenicity when given as a saline solution and adsorbed to aluminum hydroxide gel as adjuvant. The results are given in the Table 1 below and show that the vaccine complexes were immunogenic when given i.p. in mice. [0051]
    TABLE 1
    Bactericidal antibody response of mice to meningococcal outer
    membrane protein-detoxified lipooligosaccharide vaccine,
    geometric mean reciprocal titers against
    meningococcal strain 9162
    Vaccine Dose Adjuvant Day 0 Day 28 Day 42
    proteosomes- 1 μg None <8 <8  16
    dLOS
    Lot 0271 3 μg None <8 <8 128
    10 μg  None <8 <8 512
    proteosomes- 1 μg Al(OH)3 <8 <8 512
    dLOS
    Lot 0271 3 μg Al(OH)3 <8 <8 512
    10 μg  Al(OH)3 <8 64 2048 
  • 5.1.9 The complexing of the proteosomes and LOS was verified by column chromatography of the proteosomes and LOS components before and after complexing (FIG. 9). Chromatographic analysis of bulk meningococcal L8 LOS and the final proteosomes/LOS complexes on Sephacryl S300 low pressure column. The column was run in 0.05 M Tris-HCl, 0.01 M EDTA, 0.15 M NaCl buffer. The assay for protein was by absorbance at 280 nm, and the assay for LOS was by inhibition of an ELISA (enzyme linked immunosorbant assay) in which an L8 monoclonal antibody binding to purified L8 LOS adsorbed to the plastic plate was inhibited by serial dilutions of the fractions off the Sephacryl column. Before complexing, the LOS came off the column in a broad peak centered at fraction [0052] 39. After complexing, the LOS co-eluted with the proteosomes in a peak approximately centered at fraction 33.
    • 5.1.10 Specific Purpose
  • Combine bulk GMP preparations of meningococcal outer membrane protein proteosomes and detoxified meningococcal lipopolysaccharide into non-covalent complexes by removal of detergent. [0053]
    • 5.1.11 Applications
  • This GMP procedure results in the production of a bulk preparation formation of non-covalent complexes of proteosomes with detoxified meningococcal lipopolysaccharide for use as a vaccine against [0054] N. meningitides (meningococcal) infection.
    • EXAMPLE 3
  • This example is also directed to the production of proteosome-[0055] P. shigelloides vaccine. The procedure is equally applicable for scale-up using 10-1000 fold more material with appropriate scale-up of housing size of the membrane cartridge and appropriate increases in the volumes.
  • 5.8.1 Preparation of 25 mL Sterile-Filtered Empigen BB (30% Solution) [0056]
  • 5.8.1.1 Use a 100 ml Nalgene disposable filter unit with 0.2μ pore size membrane filter to sterile filter about 25 ml of Empigen BB (30% solution). [0057]
  • 5.8.2 Prepare 4 L of [0058] TEEN 2× with 2% Empigen BB (consisting of 0.1 M Tris, 0.02 M disodium EDTA, 0.3 M sodium chloride, WFI and 2% solution of empigen BB).
  • 5.8.3 Prepare a 10 L solution of “TNS” fifteen times to total 150 liters: TNS consists of 0.15 M sodium chloride, 0.05 M Tris Buffer pH 8.0±0.2 [0059]
  • 5.8.4 Prepare 10 liters of 0.5 N Sodium Hydroxide [0060]
  • 5.8.6 If necessary, thaw bulk [0061] P. shigelloides lipopolysaccharide (LPS) to prepare for complexing with proteosomes and record the lot number, and concentration of the LPS, the required amount of LPS in mg and the calculated volume of LPS to remove.
    • 5.9.0 Complexing Proteosomes
  • with [0062] P. shigelloides LPS
    • 5.9.1 Preparation of LPS for Complexing 5.9.1.2 Pool the aliquots of bulk LPS into a clean, sterile, calibrated 5 L bottle. Measure the total volume and determine the total amount of LPS.
  • 5.9.1.3 Add a volume of 2×TEEN buffer equal to the volume of LPS used in step [0063]
  • 5.9.1.2, measure combined total volume, and then add a stir bar and mix with stir bar and stir plate combination for 15±2 minutes. [0064]
    • 5.9.2 Preparation of Proteosomes for Complexing
  • 5.9.2.1 Record the total time, if any, proteosomes was allowed to thaw. [0065]
  • 5.9.2.2 Pool the aliquots of bulk proteosomes into a clean, sterile, 1 L graduated cylinder. Measure the total volume and determine the total amount of proteosomes. [0066]
  • 5.9.2.3 From the cylinder in step 5.9.2.2, transfer to another clean, sterile, 1 L graduated cylinder, a volume of proteosomes containing the amount in mg equal to the mg amount of LPS used in step 5.9.1.2. [0067]
  • 5.9.2.4 To the cylinder containing the proteosomes, add 0.22μ filtered 30% empigen BB using 30 ml empigen per L proteosomes. Mix with a stir bar for 15 ±2 minutes. [0068]
    • 5.9.3 Combine Proteosomes with the P. shigelloides LPS
  • 5.9.3.1 Under gentle stirring with a stir bar, add the proteosomes from step [0069]
  • 5.9.3.2 to the graduated 5 L bottle with the LPS and stir for 15±2 minutes. [0070]
  • 5.9.3.3 Remove four 1 ml samples and store at −75° C. for later measurement of the concentration of protein by the Lowry method and LPS by KDO assay. [0071]
    • 5.9.4 Removal of Detergent by Ultrafiltration/Diafiltration
  • 5.9.4.1 Ultrafiltration System Details System: A/G Technology, Inc. hollow fiber cartridge, 10,000 NMWC pore size, [0072] housing size 6, ultrafiltration cartridge Note:It is necessary to condition new cartridges to flush out glycerol. This can be done by flushing 6 liters of WFI through the 6 sq/ft cartridges or less with no back pressure. The permeate solution should not be recycled to the feed reservoir. Note:All ultrafiltration steps will be followed by cleaning, sanitization, and storage steps. New cartridges have to be cleaned and sanitized prior to use.
  • 5.9.4.2 Set-up and sanitize the A/G ultrafiltration system. Clean and sanitize the system by recirculating for a minimum of 60 minutes with 2-3 liters of 0.5 N Sodium Hydroxide at an initial temperature of 50±5° C. Flush the system with 4-5 liters of WFI followed by recirculating 2-3 liters of “TNS” (0.05 M Tris/normal saline buffer pH 8.0±0.2, for at least 20±5 minutes. [0073]
  • 5.9.4.3 Measure the hold up volume in the UF system (including tubing) by transferring inlet and outlet lines filled with liquid out of the reservoir and into a 1 liter graduated cylinder, then pump until the UF system is empty. [0074]
  • 5.9.4.4 Place a 2 liter side-armed vessel in a pan and pack the vessel with wet ice for the duration of the diafiltration procedure. [0075]
  • 5.9.4.5 Transfer 1.7-1.9 L of the bulk proteosome-LPS mixture from step 5.9.3.3 into the 2 L side-armed vessel. Place a two-holed stopper fitted with two 10 ml pipettes on the vessel and connect the inlet and outlet tubing from the diafiltration system to the vessel pipettes. [0076]
  • 5.9.4.6 Turn on the recirculation pump and adjust the pump setting to 4-6. Adjust the back pressure clamp to obtain an inlet pressure of 15±4 psi. Concentrate to a total volume of 1.0±0.1 L including the hold-up volume [0077]
  • 5.9.4.7 [0078] Transfer 1±0.1 L of mixture from step 5.9.3.3 to the 2 L side-armed vessel and repeat step 5.9.4.6.
  • 5.9.4.8 Continue transferring as in step 5.9.4.7 and concentrating as in step [0079]
  • 5.9.4.9 until all the proteosome-LPS mixture from step 5.9.3.3 has been transferred to the 2 L side-armed vessel and the retentate volume is 1.4±0.2 L which includes the hold-up volume [0080]
  • 5.9.4.10 Set up the ultrafiltration apparatus for continuous feed of TNS (0.05 M Tris, normal saline) into the 2 liter side-armed vessel as liquid is removed through the membrane. Set up a reservoir using a 10 liter bottle containing TNS and fitted with a tube extending to the bottom of the bottle. Connect the inlet and outlet lines from the ultrafiltration system. Turn on the recirculation pump and adjust the pump setting to 4-6. Adjust the back pressure clamp to obtain an inlet pressure of 15±4 psi. [0081]
  • 5.9.4.11 Measure the permeate flow rate on the UF unit and record the inlet pressure when the measurement is taken. [0082]
  • 5.9.4.12 Collect a 15 to 20 ml sample of the permeate every 12±0.5 liters processed, apply an in-house label (“Permeate No. P1, P2, P3 etc.”) and record the time, volume processed and maximum O.D.[0083] 600 of the sample. Verify progressive removal of empigen by testing the samples for the presence of Empigen BB using the Empigen Precipitin Test. This test consists of making serial dilutions of the permeate, and, separately, of a solution containing a known quantity of empigen BB, adding HCl to acidify the solutions and then adding serial dilutions of SDS (sodium dodecyl sulfate) to form a checkerboard-type assay. Maximum precipitate will form when equivalent amounts of empigen and SDS are present. In this manner, the amount of empigen present can be quantitated by noting the dilutions of the permeates and the SDS in which the precipitate is formed and comparing those dilutions to those of the standards. As the diafiltration progresses, the amount of empigen becomes less and the tube containing less SDS will be the tube with the maximum precipitate. The presence of precipitate is quantitated by measuring the OD at 600 nm using a spectrophotometer.
  • For the amounts of components used in this example, continue diafiltration until at least 120 liters of permeate has been processed and there is a lack of significant precipitate in the Empigen precipitin test (Maximum OD 600 nm less than 0.05). [0084]
  • 5.9.4.13 Concentrate the product to a final retentate volume of 500±50 ml including the hold-up volume (step 9.4.3). Remove a 0.5 ml sample, dilute the sample 1:10, and measure the O.D.[0085] 280.
  • 5.9.4.14 The desired minimum O.D. of the concentrated retentate is 5.7. If the O.D. is less than 5.7, continue concentrating to 400±50 ml including the hold-up volume (step 5.9.4.3) and repeat the O.D.[0086] 280.
  • 5.9.4.15 With the retentate lines out of the retentate solution and the filtrate outlet lines closed, slowly pump in the reverse direction until the cartridge and lines are empty. Transfer the feed line and retentate lines from the retentate bottle to a new clean vessel with 350±50 ml TNS. Reverse the pump and slowly recirculate the TNS for 2-3 minutes. [0087]
  • 5.9.4.16 After recirculating the TNS, stop the pump, drain the system, collect the retentate wash solution into a clean, sterile, 1 L graduated cylinder and measure the volume and the O.D.[0088] 280.
  • 5.9.4.17 Combine the original retentate solution (step 5.9.4.12 or 5.9.4.13) with the wash retentate solution (step 5.9.4.15) and measure the final volume of retentate. Store the retentate bulk at 4° C.±2° C. until aseptic filtration. [0089]
  • 5.9.4.18 Clean the filtration unit using WFI, followed by 0.5 N sodium hydroxide at an initial 50±5° C. for a minimum of 60 minutes. Rinse the cleaning agent out with of WFI then flush with 3-4 liters of 0.1 N NaOH as the storage agent. [0090]
    • 5.9.5 Sterile Filtration
  • The complexes may, if desired, be sterile filtered. Obtain the bulk complexed proteosomes and LPS and inspect for the presence of any precipitate or cloudiness. If the bulk complexed product is clear, aseptically filter it using a [0091] Millipak 40, 0.22μ filtration unit into a sterile, depyrogenated vessel. This step is to be done in a Sterile Cabinet.
    • 5.9.6 SPECIFIC PURPOSE
  • Combine bulk GMP preparations of meningococcal outer membrane protein proteosomes and [0092] P. shigelloides lipopolysaccharide (for S. sonnei) into non-covalent complexes by removal of detergent.
    • 5.9.7 APPLICATIONS
  • This GMP procedure results in the production of a bulk preparation formation of non-covalent complexes of proteosomes with [0093] P. shigelloides 2a lipopolysaccharide for use as a vaccine against Shigella sonnei infection.
    • 5.10 Immunogenicity Studies 5.10.1 Immunogenicity of Proteosome-P. shigelloides LPS Vaccine Using Hollow Fiber Ultrafiltration/Diafiltration
  • FIGS. 1 and 2 demonstrate that three different proteosome-shigella LPS vaccine preparations made using the hollow fiber (HF) diafiltration technique (HF-1, HF-2 and GMP/HF-3) to remove detergent and facilitate complexing are more effective at the lowest, most stringent dose tested, than preparations made using simple dialysis tubing (DT). In other words, stronger IgG (FIG. 1) and IgA (FIG. 2) immune responses were elicited by vaccines produced using the instant invention than by the older, less efficient technology. Since stronger immune responses result in better levels of protection, these data clearly show that the instant invention results in vaccines that are not only more efficient to make but also more powerful. Furthermore, the stronger responses are elicited by the vaccine when administered at the lowest dose (0.1 ug per dose) thereby indicating that less vaccine would be needed using the instant invention than would be required using the older technology. Since in the formulation of multivalent vaccines requires many different antigens, in order to minimize the total amount of vaccine administered, it is highly advantageous to be able to use vaccine components that are effective at lower doses. Thus, the technology of the instant invention to produce vaccines using the hollow fiber technology directly impacts and facilitates the ability to formulate multivalent vaccines having a wide range of specificities. Since it is advantageous for commercial development of vaccines to be able to lyophilize vaccines, we were gratified to discover that lyophilization of the HF vaccine complexes from a water solution, surprisingly resulted in vaccine that consistently elicited responses that were among the highest at all doses tested. Thus, higher immunogenicity for anti-LPS IgG (FIG. 1) and IgA (FIG. 2) was found when 0.1 ug of vaccine made by the HF technique (with or without lyophilization) was administered. These data are significant since the scale-up and GMP procedure of the instant invention used the HF technology as indicated in FIGS. [0094] 1 and 2 by the cross-hatched bar representing GMP/HF-3.
    • 5.10.2 Immunogenicity Studies Using Multivalent Vaccine
  • As shown in FIG. 3, Administration of the proteosome-[0095] P. shigelloides LPS (for S. sonnei shigellosis) and the proteosome- S. flexneri 2a vaccines on the same day or weeks apart results in good immunogenicity to both LPS components: S. sonnei LPS and S. flexneri 2a LPS.
    • 5.11 Electron Micrograph of Proteosome-Shigella Vaccine
  • The association of shigella LPS with proteosomes is clearly and dramatically depicted in the electron micrograph shown in FIG. 4. In this Figure, the proteosome vesicles are studded with radio-opaque black dots. These dots are god beads linked to secondary antibodies that recognize specific anti-shigella LPS antibodies. Thus, the presence of gold dots indicates the presence of shigella LPS. Since, as can be seen, the gold dots surround and dot the proteosome vesicles, the image of proteosome vaccines with LPS non-covalently linked to the proteosomes is thereby confirmed and visualized. Surprisingly, the consistent vesicular nature of the vaccines made with the HF technology of the instant invention was not found when the DT preparations using the older technology were examined by electron microscopy (unpublished results). [0096]
    • 5.12 Proteosome-P. shigelloides LPS Vaccine Protects Against Lethal Shigella sonnei Pneumonia in an Animal Model of Shigellosis
  • As can be seen in FIG. 5, the proteosome-[0097] P. shigelloides LPS vaccine consistently confers highly significant protection against lethal infection with P. shigelloides as measured in an animal model of shigellosis in which the animals are challenged with live organisms to induce lethal pneumonia. These data also demonstrate that not only are the correct and protective antibodies produced by the proteosome-P. shigelloides LPS vaccine, but also that this intranasal sub-unit vaccine can protect against lethal pneumonia.
    • 5.13 Intranasal or Oral Immunization with Proteosome- Shigella flexneri 2a LPS Vaccines Induce Anti-Shigella LPS IgG and IgA in Serium and IgA in Intestinal and Lung Lavage Fluids that can last 30-60 days Post-Immunization
  • As shown in FIG. 6, two immunizations with proteosome-[0098] shigella flexneri 2a LPS vaccines induce antibodies in sera and in lung and intestinal secretions that can last 30 to 60 days post immunization. These data show that proteosome vaccines can stimulate the common mucosal immune system to secrete specific antibodies even at locations far away from the immunizing site. Specifically, intranasal immunization can induce antibodies in intestinal secretions and vice versa. This ability expands the potential utility of proteosome vaccines to protect against pathogens that invade the host through the mucosal portals of entry throughout the body.
  • [0099] 5.14FIG. 7 shows the induction of anti-shigella LPS IgA, IgG and IgM peripheral blood ASC responses, and serum, salivary and urinary IgA and IgG antibody responses after intranasal or oral immunization of human volunteers with one or two doses proteosome-P. shigelloides LPS vaccines for Shigella sonnei using different vaccine amounts. As shown, intranasal immunization elicited responses in a dose dependant fashion with the highest dose inducing responses in all six volunteers.
  • IgA, IgG and IgM serum responses were elicited in each of the intranasal groups. In addition, strong antibody secreting cell ASC responses were induced indicating that mucosal immunization stimulated trafficking of antibody secreting cells—most notably, IgA-secreting cells. Most importantly, IgA responses were also found in salivary and, especially, urinary samples indicating that secretory IgA was produced at mucosal surfaces (since IgA does not pass through the kidney, the urinary IgA reflects local secretion of antibody and suggests that such intranasal vaccines also produce local intestinal IgA and that intranasal vaccines could be used to protect against urinary tract infections caused by gram negative organisms.) It is noteworthy that the majority of these ASC and antibody responses were found after only one immunization suggesting that booster immunization may not be necessary. IgA and IgG ASCs and urinary IgA were also found after oral immunization. The most effective use of oral administration may be as a booster immunization after nasal priming, if necessary. [0100]
  • 5.15 Demonstration of non-covalent complexing of the multimolecular proteosome proteins and LPS is shown in FIG. 8. The graph shows LPS in HPLC fractions after applying uncomplexed [0101] P. shigelloides LPS which occurs at a different part of the column elution profile than when applying the proteosome-LPS vaccine. The co-elution of LPS and proteins in HPLC fractions after applying proteosome-P. shigelloides LPS vaccine is shown with peaks that correspond to the largest protein aggregates of proteosomes. The data were measured using an inhibition ELISA to quantitate the LPS and using the OD at A280 to quantitate the proteosome proteins. The HPLC column was a Tosohaas G50000Pwx1 and the molecular weight standards are indicated by the arrows.

Claims (28)

1. A process for the preparation of proteosome-amphiphilic determinant vaccine comprising
a) forming a mixture of proteosome, a dialyzable detergent and an amphiphilic determinant,
b) subjecting the mixture to diafiltration or ultrafiltration to remove the detergent thereby forming a amphiphilic determinant-proteosome complex,
c) monitoring the amount of amphiphilic determinant-proteosome complex formation, and
d) recovering the amphiphilic determinant-proteosome complex.
2. A process for the preparation of proteosome-amphiphilic determinant vaccine according to claim 1 wherein the ultrafiltration involves tangential flow.
3. A process for the preparation of proteosome-amphiphilic determinant vaccine according to claim 1 wherein the ultrafiltration is conducted in a system selected from hollow fiber cartridge, platform membrane and membrane cartridge.
4. A process for the preparation of proteosome-amphiphilic determinant vaccine according to claim 3 wherein the ultrafiltration system is a hollow fiber cartridge with a NMWC pore size of 10,000.
5. A process for the preparation of proteosome-amphiphilic determinant vaccine according to claim 3 wherein the ultrafiltration system is a hollow fiber cartridge with a NMWC pore size of 3,000.
6. A process for the preparation of proteosome-amphiphilic determinant vaccine according to claim 1 wherein the monitoring of dialyzable detergent involves the continual measuring of permeate samples.
7. A process for the preparation of proteosome-amphiphilic determinant vaccine according to claim 1 wherein monitoring includes measuring the optical density of permeate or retentate sample.
8. A process for the preparation of proteosome-amphiphilic determinant vaccine according to claim 1 wherein the monitoring involves measuring the amount of detergent removal by mixing a permeate sample with a known amount of SDS (sodium dodecyl sulfate) to form a precipitate if detergent is present, and determining the amount of precipitation.
9. A process for the preparation of proteosome-amphiphilic determinant vaccine according to claim 8 wherein the LPS-proteosome complex is recovered when the detergent in the permeate has been essentially removed.
10. A process for the preparation of proteosome-amphiphilic determinant vaccine according to claim 1 wherein the detergent is Empigen BB.
11. A process for the preparation of proteosome-amphiphilic determinant vaccine according to claim 1 wherein the amphiphilic determinant is a lipopolysaccharide.
12. A process for the preparation of proteosome-lipopolysaccharide vaccine according to claim 11 wherein the lipopolysaccharide is obtained from a gram negative bacteria.
13. A process for the preparation of proteosome-lipopolysaccharide vaccine according to claim 12 wherein the gram negative bacteria is a plesiomonas.
14. A process for the preparation of proteosome-lipopolysaccharide vaccine according to claim 13 wherein the plesiomonas is Plesiomonas shigelloides.
15. A process for the preparation of proteosome-lipopolysaccharide vaccine according to claim 12 wherein the gram negative bacteria is a shigella.
16. A process for the preparation of proteosome-lipopolysaccharide vaccine according to claim 15 wherein the shigella is Shigella flexneri, Shigella sonnei, or Shigella boydii.
17. A process for the preparation of proteosome-lipopolysaccharide vaccine according to claim 12 wherein the gram negative bacteria is a neisseria.
18. A process for the preparation of proteosome-lipopolysaccharide vaccine according to claim 17 wherein the neisseria is Neisseria meningitidis.
19. A process for the preparation of proteosome-amphiphilic determinant vaccine according to claim 1 wherein the proteosome is derived from N. meningiditis or N. gonorrhea.
20. A process for the preparation of proteosome-amphiphilic determinant vaccine according to claim 1 wherein the recovery of the LPS-proteosome complex is effected when the monitored rate of detergent removal is decreasing or constant.
21. A process for the preparation of proteosome-amphiphilic determinant vaccine according to claim 1 further comprising
e) mixing the recovered proteosome-amphiphilic determinant complex with a physiologically acceptable carrier to form a vaccine.
22. A process for the preparation of proteosome-amphiphilic determinant vaccine according to claim 21 further comprising concentrating the LPS-proteosome complex prior to recovery of the complex.
23. A process for the preparation of proteosome-amphiphilic determinant vaccine according to claim 22 wherein the concentration is continued to a desired final concentration.
24. A process for the preparation of proteosome-amphiphilic determinant vaccine according to claim 21 wherein the process is performed with different amphiphilic determinants types to form a series of proteosome-amphiphilic determinant complexes that are assembled in step e) to form a multivalent vaccine.
25. A multivalent vaccine prepared by the process of claim 24.
26. A process for protecting against a disease comprising administering the vaccine of claim 25 in an effective amount to a recipient.
27. A process for protecting against a disease comprising administering the vaccine prepared according to the process of claim 21 to a recipient.
28. A multivalent vaccine prepared by the process of claim 21.
US09/043,529 1995-09-18 1996-09-18 Methods for the production of non-covalently complexed and multivalent proteosome sub-unit vaccines Expired - Lifetime US6476201B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US09/043,529 US6476201B1 (en) 1995-09-18 1996-09-18 Methods for the production of non-covalently complexed and multivalent proteosome sub-unit vaccines

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US385995P 1995-09-18 1995-09-18
PCT/US1996/015002 WO1997010844A1 (en) 1995-09-18 1996-09-18 Improved methods for the production of non-covalently complexed and multivalent proteosome sub-unit vaccines
US09/043,529 US6476201B1 (en) 1995-09-18 1996-09-18 Methods for the production of non-covalently complexed and multivalent proteosome sub-unit vaccines

Publications (2)

Publication Number Publication Date
US6476201B1 US6476201B1 (en) 2002-11-05
US20020164357A1 true US20020164357A1 (en) 2002-11-07

Family

ID=21707938

Family Applications (1)

Application Number Title Priority Date Filing Date
US09/043,529 Expired - Lifetime US6476201B1 (en) 1995-09-18 1996-09-18 Methods for the production of non-covalently complexed and multivalent proteosome sub-unit vaccines

Country Status (20)

Country Link
US (1) US6476201B1 (en)
EP (1) EP0854729B2 (en)
JP (2) JP4033489B2 (en)
KR (1) KR19990045763A (en)
CN (1) CN1211192A (en)
AT (1) ATE261313T1 (en)
BR (1) BR9610484A (en)
CA (1) CA2232410C (en)
CZ (1) CZ298460B6 (en)
DE (1) DE69631835T3 (en)
DK (1) DK0854729T3 (en)
EA (1) EA199800208A1 (en)
ES (1) ES2217325T5 (en)
HU (1) HUP9901577A3 (en)
IL (1) IL123720A (en)
MX (1) MX9802128A (en)
NO (1) NO320074B1 (en)
PL (1) PL325604A1 (en)
PT (1) PT854729E (en)
WO (1) WO1997010844A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060240045A1 (en) * 2002-08-02 2006-10-26 Francois-Xavier Berthet Neisserial vaccine compositions comprising a combination of antigens
CN102686238A (en) * 2009-09-09 2012-09-19 马特里瓦克斯研究和开发公司 Protein matrix vaccines of improved immunogenicity
EP2174665B1 (en) * 2003-10-22 2016-11-16 ID Biomedical Corporation of Quebec Compositions and methods for activating innate and allergic immunity

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5961970A (en) 1993-10-29 1999-10-05 Pharmos Corporation Submicron emulsions as vaccine adjuvants
US8007815B1 (en) * 1998-05-29 2011-08-30 Novartis Ag Combination meningitidis B/C vaccines
CN100392082C (en) 1999-04-30 2008-06-04 启龙股份公司 Conserved neisserial antigens
DK2270173T3 (en) * 1999-05-19 2016-03-07 Glaxosmithkline Biolog Sa Neisserial combination compositions
US6743900B2 (en) 2000-02-15 2004-06-01 Id Biomedical Corporation Of Quebec Proteosome influenza vaccine
EP1721618A3 (en) * 2000-02-15 2007-01-10 ID Biomedical Corporation of Quebec Proteosome influenza vaccine composition
MXPA02008314A (en) 2000-02-28 2002-12-09 Chiron Spa Heterologous expression of neisserial proteins.
MXPA03008154A (en) * 2001-03-09 2004-11-12 Id Biomedical Corp Quebec A novel proteosome-liposaccharide vaccine adjuvant.
CA2501812C (en) 2002-10-11 2012-07-10 Mariagrazia Pizza Polypeptide-vaccines for broad protection against hypervirulent meningococcal lineages
US7255867B2 (en) * 2002-11-15 2007-08-14 Id Biomedical Corporation Of Quebec Vaccine
GB0316560D0 (en) * 2003-07-15 2003-08-20 Chiron Srl Vesicle filtration
US7368537B2 (en) * 2003-07-15 2008-05-06 Id Biomedical Corporation Of Quebec Subunit vaccine against respiratory syncytial virus infection
JP2007505836A (en) * 2003-09-15 2007-03-15 アイディー バイオメディカル コーポレイション オブ ケベック Measles subunit vaccine
RU2387453C2 (en) 2004-06-25 2010-04-27 АйДи БАЙОМЕДИКАЛ КОРПОРЕЙШН ОФ КВЕБЕК Compositions and methods of treating neurological disturbances
JP2008505114A (en) * 2004-06-30 2008-02-21 アイディー バイオメディカル コーポレイション オブ ケベック Vaccine composition for treating coronavirus infection
US7552948B2 (en) 2006-03-29 2009-06-30 Tokai Rubber Industries, Ltd. Quick connector
CN110064053A (en) * 2006-08-07 2019-07-30 哈佛大学校长及研究员协会 The preparation and medication of protein matrix vaccines and this vaccine
MX2009001412A (en) 2006-08-07 2009-04-24 Harvard College Protein matrix vaccines and methods of making and administering such vaccines.
JP2010502425A (en) * 2006-08-30 2010-01-28 ジーイー・ヘルスケア・バイオサイエンス・コーポレイション Membrane evaluation system and method, and membrane filtration apparatus
AU2009262893B2 (en) * 2008-05-30 2015-05-21 The U.S.A., as represented by The Secretary of the Army, on behalf of Walter Reed Army Institute Of Research Meningococcal multivalent native outer membrane vesicle vaccine, methods of making and use thereof
EP4183408A1 (en) * 2014-09-24 2023-05-24 The United States of America as Represented by The Secretary of the Navy Combined enterotoxigenic escherichia coli and shigella recombinant
EP4277654A1 (en) 2021-01-18 2023-11-22 Conserv Bioscience Limited Coronavirus immunogenic compositions, methods and uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4707543A (en) * 1985-09-17 1987-11-17 The United States Of America As Represented By The Secretary Of The Army Process for the preparation of detoxified polysaccharide-outer membrane protein complexes, and their use as antibacterial vaccines
RU1522494C (en) * 1987-06-16 1994-11-15 Научно-производственное объединение "Иммунопрепарат" Method of preparing of inactivated influenza vaccine
RU2023448C1 (en) * 1987-07-30 1994-11-30 Сентро Насьональ Де Биопрепарадос Method for manufacturing vaccine against various pathogenic serotypes of group b neisser's meningitis
US5145702A (en) * 1988-09-19 1992-09-08 Opta Food Ingredients, Inc. Hydrophobic protein microparticles and preparation thereof
ES2070312T5 (en) * 1988-12-19 2003-05-16 American Cyanamid Co CLASS 1 MENINGOCOCIC EXTERNAL MEMBRANE PROTEIN VACCINE.
US5102989A (en) * 1991-03-15 1992-04-07 Merck & Co., Inc. Method of stabilizing recombinant hepatitis B virus surface proteins from recombinant host cells
CA2139517A1 (en) * 1992-07-20 1994-02-03 Paul M. Keller Immunological conjugates of ompc and hiv-specific selected principal neutralization epitopes
US5576016A (en) * 1993-05-18 1996-11-19 Pharmos Corporation Solid fat nanoemulsions as drug delivery vehicles
AU5543294A (en) * 1993-10-29 1995-05-22 Pharmos Corp. Submicron emulsions as vaccine adjuvants
US6743900B2 (en) * 2000-02-15 2004-06-01 Id Biomedical Corporation Of Quebec Proteosome influenza vaccine

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060240045A1 (en) * 2002-08-02 2006-10-26 Francois-Xavier Berthet Neisserial vaccine compositions comprising a combination of antigens
EP2174665B1 (en) * 2003-10-22 2016-11-16 ID Biomedical Corporation of Quebec Compositions and methods for activating innate and allergic immunity
CN102686238A (en) * 2009-09-09 2012-09-19 马特里瓦克斯研究和开发公司 Protein matrix vaccines of improved immunogenicity

Also Published As

Publication number Publication date
HUP9901577A3 (en) 2000-03-28
KR19990045763A (en) 1999-06-25
EP0854729B2 (en) 2008-10-22
CA2232410C (en) 2003-06-17
DK0854729T3 (en) 2004-07-12
WO1997010844A1 (en) 1997-03-27
US6476201B1 (en) 2002-11-05
IL123720A (en) 2002-02-10
CA2232410A1 (en) 1997-03-27
EP0854729A4 (en) 2000-02-02
HUP9901577A2 (en) 1999-08-30
EA199800208A1 (en) 1998-10-29
CZ298460B6 (en) 2007-10-10
JP4033489B2 (en) 2008-01-16
ES2217325T3 (en) 2004-11-01
EP0854729A1 (en) 1998-07-29
DE69631835D1 (en) 2004-04-15
JP2004099619A (en) 2004-04-02
ATE261313T1 (en) 2004-03-15
BR9610484A (en) 2001-09-11
CN1211192A (en) 1999-03-17
NO981189D0 (en) 1998-03-17
NO981189L (en) 1998-05-14
IL123720A0 (en) 1998-10-30
EP0854729B1 (en) 2004-03-10
DE69631835T2 (en) 2005-02-10
PL325604A1 (en) 1998-08-03
NO320074B1 (en) 2005-10-17
CZ81998A3 (en) 1998-10-14
PT854729E (en) 2004-08-31
JP2000507913A (en) 2000-06-27
ES2217325T5 (en) 2009-04-01
MX9802128A (en) 1998-11-29
DE69631835T3 (en) 2009-03-05

Similar Documents

Publication Publication Date Title
US6476201B1 (en) Methods for the production of non-covalently complexed and multivalent proteosome sub-unit vaccines
EP1286696B1 (en) Outer membrane vesicle vaccine against disease caused by neisseria meningitidis serogroup a and process for the production thereof
US6558677B2 (en) Vaccine against gram negative bacteria
CA2123355C (en) Preparation and uses of los-depleted outer membrane proteins of gram-negative cocci
Frasch et al. Protection against group B meningococcal disease. III. Immunogenicity of serotype 2 vaccines and specificity of protection in a guinea pig model.
Frasch et al. Protection against group B Neisseria meningitidis disease: preparation of soluble protein and protein-polysaccharide immunogens
BE1022875B1 (en) COMPOSITIONS FOR IMMUNIZATION AGAINST STAPHYLOCOCCUS AUREUS
Frasch et al. Outer membrane protein vesicle vaccines for meningococcal disease
EP0688206B1 (en) Vaccine delivery system and shelf-stable precursor solution for remote encapsulation of active ingredients
JPS58162531A (en) Manufacture of polysaccharide-protein composite body derived from germ capsule, products therefrom and immunogenic composition
MXPA03006038A (en) Immunizing compositions and methods of use.
Muttilainen et al. TheNeisseria meningitidisouter membrane protein P1 produced inBacillus subtilisand reconstituted into phospholipid vesicles elicits antibodies to native P1 epitopes
AU751063B2 (en) Improved methods for the production of non-covalently complexed and multivalent proteosome sub-unit vaccines
Jiskoot et al. Immunogenic activity of gonococcal protein I in mice with three different lipoidal adjuvants delivered in liposomes and in complexes
US7112332B1 (en) Oral or intranasal vaccines using hydrophobic complexes having proteosomes and lipopolysaccharides
WO2005042571A1 (en) Method of antigen incorporation into neisseria bacterial outer membrane vesicles and resulting vaccine formulations
Manoharan et al. Characterisation and Immunogenicity of Neisseria cinerea outer membrane vesicles displaying NadA, NHBA and fHbp from Neisseria meningitidis serogroup B
Straube et al. Effect of immunization with Escherichia coli K1 antigen on the course of experimental infection of the urinary tract of the rat

Legal Events

Date Code Title Description
AS Assignment

Owner name: ID BIOMEDICAL CORPORATION OF QUEBEC, CANADA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:LOWELL, GEORGE H.;REEL/FRAME:012938/0587

Effective date: 20020726

STCF Information on status: patent grant

Free format text: PATENTED CASE

AS Assignment

Owner name: ID BIOMEDICAL CORPORATION OF MARYLAND, MARYLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ID BIOMEDICAL CORPORATION OF QUEBEC;REEL/FRAME:013463/0113

Effective date: 20030304

AS Assignment

Owner name: UNITED STATES ARMY, MARYLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ZOLLINGER, WENDELL D.;REEL/FRAME:014543/0323

Effective date: 20020724

FPAY Fee payment

Year of fee payment: 4

FPAY Fee payment

Year of fee payment: 8

FPAY Fee payment

Year of fee payment: 12